Q-omics provides the consensus-scored CXorf65 profile across patient tissues and cancer cell-line models. CXorf65 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CXorf65 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CXorf65 RNA expression shows 16,131 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where CXorf65 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CXorf65 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CXorf65 survival associations across molecular data types. CXorf65 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CXorf65 RNA expression–survival associations across cancer types. High CXorf65 expression shows unfavorable associations in UVM, LGG and KIRC, but favorable associations in HNSC, OV and CESC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CXorf65 RNA expression.
This table summarizes CXorf65 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CXorf65. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CXorf65 shows lower tumor expression in KICH and LUSC and higher tumor expression in KIRC, STAD, COAD and BRCA. The KIRC box plot shows higher CXorf65 RNA expression in tumor versus normal tissue (log2 FC = +0.351, t-test p < 0.001).
This table shows molecular features associated with CXorf65 in patient tissues and cancer cell lines. In patient samples, CXorf65 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, CXorf65 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
